Rescue

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Colorectal CancerAsthmaBladder CancerCervical CancerEsophageal Squamous Cell CarcinomaGastroesophageal AdenocarcinomaBreast NeoplasmsMalignant NeoplasmNon Muscle Invasive Bladder CancerLung Neoplasm MalignantOvarian NeoplasmsOesophageal Squamous Cell Carcinoma

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

1

Stivarga

Bayer

Phase 3

392

Adrucil

EElorac, Inc.

Phase 3

873

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

584

Bayer Aspirin

Bayer

Phase 3

75

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

86

Decadron

AAspen Global Incorporated

Phase 3

77

Botensilimab

AAgenus Inc.

Phase 3

108

Balstilimab

AAgenus Inc.

Phase 3

109

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

Phase 3

410

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

2Show 40 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease4 trials

Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)

Terminated·Merck & Co.·Phase 2·NCT00441701·99 enrolled

Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)

Terminated·GSK·Phase 2·NCT03250689·19 enrolled

A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)

Terminated·GSK·Phase 2·NCT03170232·54 enrolled

Show 1 more trial

Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Completed·GSK·Phase 2·NCT03034967·614 enrolled

Migraine3 trials

Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)

Completed·Merck & Co.·Phase 3·NCT00442936·1,380 enrolled

A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)

Completed·AbbVie·Phase 2·NCT01613248·834 enrolled

A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)

Completed·AbbVie·Phase 2·NCT01657370·195 enrolled

Asthma3 trials

Neutrophilic Asthma Study With Navarixin (MK-7123, SCH 527123) (MK-7123-017)(COMPLETED)

Completed·Merck & Co.·Phase 2·NCT00632502·37 enrolled

A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma

Withdrawn·GSK·Phase 2·NCT02794519

A Double-dummy, Double-blind, Randomized, Active Controlled, Two-way Cross-over Study With 12 Week Treatment Duration Period, to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Compared to Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

Recruiting·Novartis·Phase 3·NCT05776927·188 enrolled

Bipolar Disorder2 trials

Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)

Completed·OOrganon and Co·Phase 3·NCT01244815·404 enrolled

Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)

Completed·OOrganon and Co·Phase 3·NCT01349907·322 enrolled

Chemotherapy-induced nausea and vomiting2 trials

Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)

Completed·Merck & Co.·Phase 3·NCT00080444·50 enrolled

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

Completed·Merck & Co.·Phase 3·NCT01594749·1,015 enrolled

29 more indications

Bladder Cancer2 trials

A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator's Choice of Non-platinum Chemotherapy in Participants With Pretreated Locally Advanced/Metastatic Urothelial Carcinoma

Recruiting·Merck & Co.·Phase 3·NCT07419295·590 enrolled

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents in Combination With Enfortumab Vedotin Plus Pembrolizumab as First-Line Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma: KEYMAKER-U04-Substudy 04D

Recruiting·Merck & Co.·Preclinical·NCT07232602·55 enrolled

Type 1 Diabetes Mellitus1 trial

A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001)

Completed·Merck & Co.·Phase 1·NCT02269735·74 enrolled

Moderate to Severe COPD1 trial

Long-Term Study of the Effects of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe COPD (MK-7123-019)

Terminated·Merck & Co.·Phase 2·NCT01006616·616 enrolled

Cardiac Dysfunction1 trial

Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction

Unknown status·NNational Cheng-Kung University Hospital·N/A·NCT05892146·100 enrolled

Sedation1 trial

Study Comparing Atomizerd Midazolam & Fentanyl and Dexmedomidine for Procedural Sedation in Adult and Pediatric Patient (2 to 60 Years Old)

Not yet recruiting·OOman Medical Speciality Board·N/A·NCT07166666·128 enrolled

Esophageal Adenocarcinoma1 trial

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Active, not recruiting·Merck & Co.·Phase 3·NCT06356311·450 enrolled

Vomiting1 trial

Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)

Terminated·Merck & Co.·Phase 2·NCT01405924·111 enrolled

Allergic Rhinitis1 trial

Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)

Completed·AALK-Abelló A/S·Phase 4·NCT02256553·102 enrolled

Type 2 Diabetes Mellitus1 trial

A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)

Completed·Merck & Co.·Phase 2·NCT00481663·555 enrolled

Lung Neoplasm1 trial

KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)

Recruiting·Merck & Co.·Phase 2·NCT06780098·144 enrolled

Diffuse Large B-Cell Lymphoma1 trial

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

Recruiting·Merck & Co.·Phase 3·NCT06717347·1,046 enrolled

Esophageal Squamous Cell Carcinoma1 trial

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Recruiting·Merck & Co.·Preclinical·NCT06780111·298 enrolled

Ovarian Neoplasms1 trial

A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced Non-HRD Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/GOG-3102)

Recruiting·Merck & Co.·Phase 3·NCT07318558·900 enrolled

Castration Resistant Prostatic Cancer1 trial

MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)

Recruiting·Merck & Co.·Preclinical·NCT06863272·360 enrolled

Oesophageal Squamous Cell Carcinoma1 trial

A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F

Recruiting·Merck & Co.·Preclinical·NCT07405151·60 enrolled

Cervical Cancer1 trial

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)

Recruiting·Merck & Co.·Phase 3·NCT07216703·1,023 enrolled

Prostate Cancer1 trial

A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)

Recruiting·Merck & Co.·Phase 3·NCT06925737·1,440 enrolled

Colorectal Cancer1 trial

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Recruiting·Merck & Co.·Preclinical·NCT06428409·220 enrolled

Non-Small Cell Lung Cancer1 trial

A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery

Recruiting·Merck & Co.·Phase 3·NCT06312137·780 enrolled

Lymphoma, Large B-Cell, Diffuse1 trial

A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting·Merck & Co.·Phase 2·NCT06890884·594 enrolled

Triple Negative Breast Neoplasms1 trial

A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)

Recruiting·Merck & Co.·Phase 3·NCT06841354·1,000 enrolled

Ovarian Cancer Recurrent1 trial

A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With Advanced High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (REJOICE-Ovarian02)

Recruiting·Merck & Co.·Preclinical·NCT06843447·605 enrolled

Breast Neoplasms1 trial

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Recruiting·Merck & Co.·Phase 3·NCT06966700·2,400 enrolled

Gastroesophageal Adenocarcinoma1 trial

A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D

Recruiting·Merck & Co.·Preclinical·NCT06445972·210 enrolled

Lung Neoplasm Malignant1 trial

KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations

Recruiting·Merck & Co.·Preclinical·NCT07286149·140 enrolled

Malignant Neoplasm1 trial

A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)

Recruiting·Merck & Co.·Phase 2·NCT06979596·250 enrolled

Non Muscle Invasive Bladder Cancer1 trial

A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Recruiting·Merck & Co.·Preclinical·NCT06637423·32 enrolled

Neoplasm Metastasis1 trial

A Phase 1 Open-label, Multicenter Study of MK-6837 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors

Completed·Merck & Co.·Phase 1·NCT06460961·40 enrolled

Small Cell Lung Cancer Extensive Stage1 trial

A Phase 1b/2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer

Recruiting·Merck & Co.·Preclinical·NCT07227597·170 enrolled

Details

Drug Info

Related News